BridgeBio Pharma Announces New Equity Compensation Plan for Employees with Inducement Grants

Reuters

2025/09/11

<a href="https://laohu8.com/S/BBIO">BridgeBio Pharma</a> Announces New Equity Compensation Plan for Employees with Inducement Grants

BridgeBio Pharma Inc., a biopharmaceutical company focused on genetic diseases, has announced the approval of new equity compensation grants for its employees. The company's board of directors' compensation committee has approved restricted stock units (RSUs) for new employees as part of its Amended and Restated 2019 Inducement Equity Plan. The recent approvals include RSU grants covering a total of 33,684 shares for 13 employees on September 5, 2025, 32,145 shares for 16 employees on August 4, 2025, and 73,991 shares for 20 employees on July 14, 2025. Additionally, on June 6, 2025, RSU grants covering 98,348 shares were approved for 25 employees. The vesting schedule for these RSUs begins with one-fourth of the shares vesting in mid-2026, and the remainder vesting in equal quarterly installments over three years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526068-en) on September 10, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2566984454"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566984454\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566984454?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-11 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566984454","market":"us","top_or_hot":-1,"title":"BridgeBio Pharma Announces New Equity Compensation Plan for Employees with Inducement Grants","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> Announces New Equity Compensation Plan for Employees with Inducement Grants\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BridgeBio Pharma Inc., a biopharmaceutical company focused on genetic diseases, has announced the approval of new equity compensation grants for its employees. The company's board of directors' compensation committee has approved restricted stock units (RSUs) for new employees as part of its Amended and Restated 2019 Inducement Equity Plan. The recent approvals include RSU grants covering a total of 33,684 shares for 13 employees on September 5, 2025, 32,145 shares for 16 employees on August 4, 2025, and 73,991 shares for 20 employees on July 14, 2025. Additionally, on June 6, 2025, RSU grants covering 98,348 shares were approved for 25 employees. The vesting schedule for these RSUs begins with one-fourth of the shares vesting in mid-2026, and the remainder vesting in equal quarterly installments over three years.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526068-en) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio Pharma Announces New Equity Compensation Plan for Employees with Inducement Grants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio Pharma Announces New Equity Compensation Plan for Employees with Inducement Grants\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-11 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> Announces New Equity Compensation Plan for Employees with Inducement Grants\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BridgeBio Pharma Inc., a biopharmaceutical company focused on genetic diseases, has announced the approval of new equity compensation grants for its employees. The company's board of directors' compensation committee has approved restricted stock units (RSUs) for new employees as part of its Amended and Restated 2019 Inducement Equity Plan. The recent approvals include RSU grants covering a total of 33,684 shares for 13 employees on September 5, 2025, 32,145 shares for 16 employees on August 4, 2025, and 73,991 shares for 20 employees on July 14, 2025. Additionally, on June 6, 2025, RSU grants covering 98,348 shares were approved for 25 employees. The vesting schedule for these RSUs begins with one-fourth of the shares vesting in mid-2026, and the remainder vesting in equal quarterly installments over three years.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526068-en) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDLQsbSJ:1","article_id":"2566984454","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566984454","pubTimestamp":1757534472,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BridgeBio Pharma Inc., a biopharmaceutical company focused on genetic diseases, has announced the approval of new equity compensation grants for its employees. The company's board of directors' compensation committee has approved restricted stock units  for new employees as part of its Amended and Restated 2019 Inducement Equity Plan. The recent approvals include RSU grants covering a total of 33,684 shares for 13 employees on September 5, 2025, 32,145 shares for 16 employees on August 4, 2025, and 73,991 shares for 20 employees on July 14, 2025. Additionally, on June 6, 2025, RSU grants covering 98,348 shares were approved for 25 employees. The vesting schedule for these RSUs begins with one-fourth of the shares vesting in mid-2026, and the remainder vesting in equal quarterly installments over three years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BBIO":"BridgeBio Pharma, Inc.","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据"},"translate_title":"BridgeBio Pharma宣布为员工提供新的股权补偿计划并提供奖励","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":0.9,"NDAQ":0.9},"content_text":"BridgeBio Pharma Announces New Equity Compensation Plan for Employees with Inducement Grants\n    \n\n        BridgeBio Pharma Inc., a biopharmaceutical company focused on genetic diseases, has announced the approval of new equity compensation grants for its employees. The company's board of directors' compensation committee has approved restricted stock units (RSUs) for new employees as part of its Amended and Restated 2019 Inducement Equity Plan. The recent approvals include RSU grants covering a total of 33,684 shares for 13 employees on September 5, 2025, 32,145 shares for 16 employees on August 4, 2025, and 73,991 shares for 20 employees on July 14, 2025. Additionally, on June 6, 2025, RSU grants covering 98,348 shares were approved for 25 employees. The vesting schedule for these RSUs begins with one-fourth of the shares vesting in mid-2026, and the remainder vesting in equal quarterly installments over three years.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526068-en) on September 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}